跳到主要导航 跳到搜索 跳到主要内容

Performance of the China-CLIF framework in acute-on-chronic liver failure: a multicohort study across all aetiologies

  • The CANONIC, PREDICT, ACLARA Study Group, Chinese Group on the Study of Severe Hepatitis B (COSSH)
  • Zhejiang University
  • The First Affiliated Hospital of Soochow University
  • Hainan Medical University
  • Central South University
  • Fudan University
  • The First Affiliated Hospital of Xi’an Jiaotong University
  • Anhui Medical University
  • European Foundation for the Study of Chronic Liver Failure (EF CLIF)
  • General Hospital of People's Liberation Army
  • Hangzhou Medical College
  • Huazhong University of Science and Technology
  • Wenzhou Medical University
  • Imperial College London
  • Pacific Care Home
  • Nanchang University
  • Sir Run Run Shaw Hospital
  • Nanfang Hospital
  • Taizhou Hospital
  • University of Padua
  • University College London
  • The Third Affiliated Hospital of Sun Yat-sen University
  • Capital Medical University
  • Zhejiang University-University of Toronto Joint Institute of Genetics and Genomic Medicine
  • Universidade de São Paulo
  • University of Münster
  • Université Paris Cité
  • Department of Hepatobiliopancreatic Surgery

科研成果: 期刊稿件文章同行评审

8 引用 (Scopus)

摘要

Background Acute-on-chronic liver failure (ACLF) of various aetiologies is a complex syndrome with high short-term mortality and significant global burden. Objective To explore easily applicable diagnostic criteria and an accurate prognostic score for ACLF. Design Clinical data from 5288 patients (after exclusions from 7388 screened) with acute deterioration of chronic liver disease across various aetiologies were used to evaluate the performance of European Chronic Liver Failure (CLIF) and Chinese Group on the Study of Severe Hepatitis B (COSSH) criteria. Three non-Asian cohorts were performed to validate the results. Results CLIF criteria categorised 844 patients as ACLF (28-day/90-day liver transplantation (LT)-free mortality: 40.7%/57.0%; 321 with non-hepatitis B virus (HBV) aetiology, 523 with HBV aetiology), while COSSH criteria categorised 2038 patients as ACLF (mortality: 27.3%/41.0%; 602 with non-HBV aetiology, 1436 with HBV aetiology). COSSH criteria identified 22.6% (1194/5288) more patients (mortality: 19.1%/31.4%) compared with CLIF criteria, including 14.2% non-HBV patients (mortality: 15.9%/33.3%). COSSH criteria produced a more reasonable epidemiological pyramid-like distribution across severity grades (grades 1–3: 63.4%/27.5%/9.1% vs CLIF’s grades 1–3: 25.8%/56.3%/17.9%). COSSH-ACLF II score showed the highest predictive values for 28-day/90-day LT-free mortality in both cirrhotic and all ACLF patients with various aetiologies, outperforming the CLIF-C ACLF and other scores. The comparable performance of China-CLIFs (renamed from COSSH-ACLFs) was validated in three non-Asian cohorts. Conclusions This study evaluated the broader applicability of the China-CLIF framework across diverse aetiologies and varying severity levels of ACLF. These findings may provide a valuable foundation for harmonising ACLF diagnostic and prognostic system.

源语言英语
页(从-至)131-146
页数16
期刊Gut
75
1
DOI
出版状态已出版 - 1 1月 2026
已对外发布

联合国可持续发展目标

此成果有助于实现下列可持续发展目标:

  1. 可持续发展目标 3 - 良好健康与福祉
    可持续发展目标 3 良好健康与福祉

学术指纹

探究 'Performance of the China-CLIF framework in acute-on-chronic liver failure: a multicohort study across all aetiologies' 的科研主题。它们共同构成独一无二的学术指纹。

引用此